Wenyan Wang | Biological Information | Best Researcher Award

Posted on by sciencefather

Dr. Wenyan Wang | Biological Information | Best Researcher Award 

Wang Wenyan is a PhD student at Anhui University of Technology, specializing in Metallurgical Engineering with a focus on Metallurgical Intelligent Manufacturing. She holds a master’s degree in Control Theory and Control Engineering and a bachelor’s degree in Automation from the same university. Her research centers on artificial intelligence applications in industrial automation and defect detection. She has contributed to patents on apple leaf disease identification using convolutional neural networks and steel surface defect detection. Proficient in C programming and fluent in English (CET-6), she combines technical expertise with innovation in intelligent manufacturing.

Dr. Wenyan Wang | Anhui University of technology | China

Profile

SCOPUS ID

🎓Education

  • Wang Wenyan is currently a PhD student at Anhui University of Technology, specializing in Metallurgical Engineering with a focus on Metallurgical Intelligent Manufacturing. She pursued her master’s degree at the same university from September 2015 to June 2018 in Control Theory and Control Engineering. Her academic journey began at the Anhui University of Technology Business School, where she earned a bachelor’s degree in Automation from September 2011 to June 2015.

👨‍🏫Experience

  • Throughout her academic career, Wang Wenyan has been deeply involved in research and development, particularly in the areas of intelligent manufacturing and industrial automation. Her work integrates advanced control theories and computational techniques to enhance metallurgical processes.

🏆Awards and Recognitions

  • Wang Wenyan has contributed to groundbreaking research in the field of intelligent manufacturing, securing patents that demonstrate her innovative capabilities. She played a key role in the development of a convolutional neural network-based method for identifying apple leaf diseases, which was authorized in 2021. Additionally, she co-developed a method for detecting surface defects in steel products, balancing speed and accuracy, which is currently under examination.

💡Skills and Certifications

  • With a strong technical background, Wang Wenyan is proficient in C programming and has achieved a Level 2 certification. She also has a solid command of the English language, having passed the CET-6 exam. Her expertise lies in control engineering, artificial intelligence applications, and industrial automation.

🔬 Research Focus

  • Her research is centered on intelligent manufacturing within the metallurgical industry, particularly in the application of artificial intelligence and control systems to optimize industrial processes. She is actively engaged in developing advanced defect detection techniques and automation solutions that enhance efficiency and precision in metallurgical engineering.

🌎Conclusion

  • With her strong technical skills, research impact, and pioneering work in intelligent automation, Dr. Wang Wenyan is a highly deserving candidate for the Best Researcher Award. Her contributions hold significant promise for enhancing industrial efficiency, quality control, and smart manufacturing systems.

📖Publications

  • Prediction of colorectal cancer microsatellite instability and tumor mutational burden from histopathological images using multiple instance learning
    Authors: W. Wang, Wenyan; W. Shi, Wei; C. Nie, Chuanqi; B. Wang, Bing; J. Yang, Jialiang
    Journal: Biomedical Signal Processing and Control, 2025

  • SOKD: A Soft Optimization Knowledge Distillation Scheme for Surface Defects Identification of Hot-Rolled Strip
    Authors: W. Wang, Wenyan; Z. Ren, Zheng; C. Wang, Cheng; X. Pan, Xuejuan; B. Wang, Bing
    Journal: ISIJ International, 2025

  • Improving bearing fault diagnosis method based on the fusion of time–frequency diagram and a novel vision transformer
    Authors: J. Wang, Jingyuan; Y. Zhao, Yuan; W. Wang, Wenyan; Z. Wu, Ziheng
    Journal: Journal of Supercomputing, 2025

Zongzhi Liu | Bioinformatics | Best Researcher Award

Posted on by sciencefather

Assoc Prof Dr.Zongzhi Liu | Bioinformatics | Best Researcher Award

Successful Research Projects:
  • Dr. Liu has led significant projects, including the study of RUNX3 methylation’s impact on T cell function and immunotherapy response. His successful acquisition of funding for multiple National Natural Science Foundation projects reflects his ability to secure resources for impactful research.
Assoc Prof Dr. Zongzhi Liu , Changping Laboratory, China

Profile

Scopus

🏛️Early Academic Pursuits

  • Zongzhi Liu’s academic journey is deeply rooted in the exploration of human diseases and immunotherapy. His early academic work laid the foundation for his current focus on the mechanisms of neurodegenerative diseases and tumor immunotherapy. By leveraging next-generation sequencing and bioinformatics, he has significantly contributed to the understanding of disease pathways and therapeutic targets.

👨‍🔬  Professional Endeavors

  • Liu’s professional endeavors are characterized by his commitment to precision medicine and epigenetic research. His notable projects include the development of epigenetic biomarkers for early cancer diagnosis and targeted therapy. His work with Runx3 knockout mouse models has provided critical insights into the epigenetic regulation of PD-1 tumor treatment response and resistance.

🔬 SCADEN Algorithm and Neurodegenerative Diseases

  • Liu utilized the SCADEN algorithm to predict primary pathways involved in neuron degeneration, specifically focusing on Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). His research integrates behavioral experiments in mice to explore these mechanisms further.

🧫 Multi-Omics Analysis for Tumor Immunotherapy

  • Through multi-omics analysis, Liu identified epigenetic targets for tumor immunotherapy. His establishment of a Runx3 knockout mouse model was pivotal in demonstrating that Runx3 epigenetic reprogramming is a key regulator of PD-1 tumor treatment response and resistance.

🌐 Research and Innovations

  • Liu’s innovations extend to several high-impact projects:

    • Molecular Mechanism of T Cell Function: Studied the regulation of T cell function related to RUNX3 methylation reprogramming, funded by the National Natural Science Foundation (2023-2025).
    • Emerging Infectious Diseases: Contributed to pathogen identification and early warning technology for infectious diseases, as part of a national task (2021-2024).
    • Combined Immunotherapy: Investigated the synergistic effects of combined immunotherapy, with significant clinical implications (2016-2022).
    • Maternal Age and Pregnancy Outcomes: Explored the impact of advanced maternal age on pregnancy outcomes and offspring health (2018-2022).
    • Liquid Biopsy Technology: Evaluated liquid biopsy technology for early cancer screening and diagnosis (2019-2021).

🏢 Consultancy/Industry Projects

  • National Natural Science Foundation Project: Molecular mechanism study on T cell function regulation (2023-2025).
  • National Task Project: Study on pathogen identification and early warning technology (2021-2024).
  • National Key R&D Program: Research on combined immunotherapy (2016-2022).
  • National Natural Science Foundation Key Project: Impact of advanced maternal age on pregnancy outcomes (2018-2022).
  • Ministry of Science and Technology Key R&D Program: Liquid biopsy technology for early cancer diagnosis (2019-2021).

🌍 Impact and Influence

  • Liu’s research has significantly impacted the fields of neurodegenerative diseases and tumor immunotherapy. His work on epigenetic reprogramming and precision medicine has paved the way for innovative approaches to early diagnosis and targeted therapy, influencing both clinical practices and future research directions.

👩‍🔬 Professional Memberships AND Collaborations

  • Zongzhi Liu holds esteemed editorial appointments as a reviewer for Frontiers in Oncology and Frontiers in Pediatrics, contributing his expertise to the peer-review process. His collaborative efforts span multiple prestigious institutions, including the General Hospital of the People’s Liberation Army of China, the Institute of Pathogen Biology at the Chinese Academy of Medical Sciences, Peking University Third Hospital, and the Cancer Hospital of the Chinese Academy of Medical Sciences. As a member of the Chinese Society for Cell Biology, Liu actively participates in advancing the field of bioinformatics in human diseases. His research focuses on bioinformatics, with a particular interest in the mechanisms of neurodegenerative diseases and tumor immunotherapy, underscoring his commitment to the intersection of epigenetics and precision medicine.

🌟 Legacy and Future Contributions

  • Liu’s legacy in the scientific community is marked by his groundbreaking research and dedication to advancing medical science. His future contributions are anticipated to further enhance our understanding of disease mechanisms and therapeutic strategies, ultimately improving patient outcomes and shaping the future of precision medicine.

📄Publications

  • Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy
    • Authors: Liu, Z., Li, X., Gao, Y., Mei, Q., Sun, Y.
    • Journal: Molecular Cancer, 2023, 22(1), 84
  • CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection
    • Authors: Liu, Z., Gao, X., Kan, C., Zhang, Z., Sun, Y.
    • Journal: MedComm, 2023, 4(1), e208
  • Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
    • Authors: Jing, C., Wang, J., Zhu, M., Zhang, Z., Deng, W.
    • Journal: Cancer Immunology, Immunotherapy, 2022, 71(11), pp. 2597–2608
  • Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer
    • Authors: Hai, L., Li, L., Liu, Z., Tong, Z., Sun, Y.
    • Journal: MedComm, 2022, 3(3), e134
  • Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
    • Authors: Wang, Y., Tong, C., Dai, H., Zhang, Y., Han, W.
    • Journal: Nature Communications, 2021, 12(1), 409